GSK, Pfizer Lock Horns Over Patent Fight Related To Respiratory Syncytial Virus Vaccine
Portfolio Pulse from Vandana Singh
GSK Plc has sued Pfizer Inc, alleging that Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo violates GSK's four patent rights in its RSV shot Arexvy. Both vaccines were approved by the FDA in May for use in adults over 60. The RSV vaccine market could exceed $10 billion by 2030. The lawsuit should not affect GSK's ability to launch Arexvy. Pfizer has also filed an action against GSK in the Royal Courts of Justice in London, claiming that European counterparts to the patents are invalid.
August 04, 2023 | 11:35 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer has been sued by GSK over patent rights for its RSV vaccine. Pfizer has also filed an action against GSK in London.
The lawsuit filed by GSK could potentially impact Pfizer's ability to market its RSV vaccine. Additionally, Pfizer's own legal action against GSK in London adds another layer of uncertainty. Therefore, the short-term impact on Pfizer's stock price is expected to be negative.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100
NEUTRAL IMPACT
GSK has sued Pfizer over patent rights for its RSV vaccine. This legal action should not affect GSK's ability to launch its vaccine.
The lawsuit is directly related to GSK's patent rights for its RSV vaccine. However, a spokesperson for GSK has stated that this should not affect the company's ability to launch its vaccine. Therefore, the short-term impact on GSK's stock price is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100